Beyond lung function in COPD management: Effectiveness of LABA/LAMA combination therapy on patient-centred outcomes

Primary Care Respiratory Journal

Volumn 21, Issue 1, 2012, Pages 101-108

  van der Molen, Thys ^a   Cazzola, Mario ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Bronchodilators; Combination therapy; COPD; Long acting muscarinic antagonists; Patient centred outcomes

Indexed keywords

ARFORMOTEROL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; INDACATEROL; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; SALMETEROL; SHORT ACTING DRUG; TIOTROPIUM BROMIDE;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE EXACERBATION; DRUG EFFICACY; DYSPNEA; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMAN; INSPIRATORY CAPACITY; LUNG FUNCTION; LUNG VOLUME; MONOTHERAPY; MORNING DOSAGE; PRIMARY MEDICAL CARE; QUALITY OF LIFE; SPIROMETRY; SYMPTOMATOLOGY; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 85027923918     PISSN: 14714418     EISSN: 14751534     Source Type: Journal    
DOI: 10.4104/pcrj.2011.00102     Document Type: Article

References (39)

1. GOLD. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. 2009.
2. van Noord JA, Aumann JL, Janssens E, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006;129(3):509-17. http://dx.doi.org/10.1378/chest.129.3.509
3. Cazzola M, Matera MG. Long-acting bronchodilators are the first-choice option for the treatment of stable COPD. Chest 2004;125(1):9-11. http://dx.doi.org/10.1378/chest.125.1.9
4. Hanania NA, Donohue JF. Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators. Proc Am Thorac Soc 2007;4(7):526-34. http://dx.doi.org/10.1513/pats.200701-016FM
5. Cazzola M, Molimard M. The scientific rationale for combining long-acting beta2- agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther 2010;23(4):257-67. http://dx.doi.org/10.1016/j.pupt.2010.03.003
6. Wang J, Jin D, Zuo P, et al. Comparison of tiotropium plus formoterol to tiotropium alone in stable chronic obstructive pulmonary disease: a meta-analysis. Respirology 2010;16(2):350-8. http://dx.doi.org/10.1111/j.1440-1843.2010.01912.x
7. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007;146(8):545-55.
8. Vogelmeier C, Kardos P, Harari S, et al. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med 2008;102(11):1511-20. http://dx.doi.org/10.1016/j.rmed.2008.07.020
9. Jones PW, Agusti AG. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J 2006;27(4):822-32. http://dx.doi.org/10.1183/?09031936.06.00145104
10. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31(2):416-69. http://dx.doi.org/10.1183/?09031936.00099306
11. Jones PW, Kaplan RM. Methodological issues in evaluating measures of health as outcomes for COPD. Eur Respir J Suppl 2003;41:13-8s. http://dx.doi.org/10.1183/?09031936.03.00077803
12. Calverley PM. Dynamic hyperinflation: is it worth measuring? Proc Am Thorac Soc 2006;3(3):239-44. http://dx.doi.org/10.1513/pats.200508-084SF
13. Duranti R, Filippelli M, Bianchi R, et al. Inspiratory capacity and decrease in lung hyperinflation with albuterol in COPD. Chest 2002;122(6):2009-14. http://dx.doi.org/10.1378/chest.122.6.2009
14. Stubbing DG, Pengelly LD, Morse JL, Jones NL. Pulmonary mechanics during exercise in subjects with chronic airflow obstruction. J Appl Physiol 1980;49(3):511-5.
15. Tashkin DP, Donohue JF, Mahler DA, et al. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. Respir Med 2009;103(4):516-24. http://dx.doi.org/10.1016/j.rmed.2008.12.014
16. Berton DC, Reis M, Siqueira AC, et al. Effects of tiotropium and formoterol on dynamic hyperinflation and exercise endurance in COPD. Respir Med 2010;104(9):1288-96. http://dx.doi.org/10.1016/j.rmed.2010.05.017
17. Hanania NA, Boota A, Kerwin E, Tomlinson L, is-Mize K. Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: results from a 6-week, randomized, placebo-controlled, clinical trial. Drugs 2009;69(9):1205-16. http://dx.doi.org/10.2165/00003495-200969090-00005
18. Mahler DA, D'Urzo A, Peckitt C, et al. Combining once-daily bronchodilators in COPD: indacaterol plus tiotropium versus tiotropium alone. Am J Respir Crit Care Med 2011;183:A1591
19. Tashkin DP, Pearle J, Iezzoni D, Varghese ST. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD 2009;6(1):17-25. http://dx.doi.org/10.1080/15412550902724073
20. Tashkin DP, Littner M, Andrews CP, et al. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir Med 2008;102(4):479-87. http://dx.doi.org/10.1016/j.rmed.2007.12.019
21. van Noord J, Aumann L, Janssens E, et al. Combination therapy of tiotropium plus salmeterol superior to single agent therapy in terms of dyspnea improvement in COPD (abstract). Chest 2005;128:177S.
22. van Noord JA, Aumann JL, Janssens E, et al. Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms. Respir Med 2010;104(7):995-1004. http://dx.doi.org/10.1016/j.rmed.2010.02.017
23. van Noord JA, Aumann JL, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005;26(2):214-22. http://dx.doi.org/10.1183/?09031936.05.00140404
24. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St George's Respiratory Questionnaire. Am Rev Respir Dis 1992;145(6):1321-7.
25. van der Molen T, Willemse BW, Schokker S, et al. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes 2003;1:13. http://dx.doi.org/10.1186/1477-7525-1-13
26. Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD Assessment Test. Eur Respir J 2009;34(3):648-54. http://dx.doi.org/10.1183/09031936.00102509
27. Van de Maele B, Fabbri LM, Martin C, et al. Cardiovascular safety of QVA149, a combination of indacaterol and NVA237, in COPD patients. COPD 2010;7(6):418-27. http://dx.doi.org/10.3109/15412555.2010.528812
28. Cazzola M, Matera MG. Emerging inhaled bronchodilators: an update. Eur Respir J 2009;34(3):757-69. http://dx.doi.org/10.1183/?09031936.00013109
29. van Noord JA, Buhl R, Laforce C, et al. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax 2010;65(12):1086-91. http://dx.doi.org/10.1136/thx.2010.139113
30. Maltais F, Beck E, Webster D, et al. Four weeks once daily treatment with tiotropium+olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients (abstract). Eur Respir J 2010;36:5557.
31. Clinicaltrials.gov. www.clinicaltrials.gov 2011.
32. Philip J, Gray A, Clarke N, Yeadon M, Perros-Huguet C. Demonstration of dual pharmacology in vivo of PF-3429281: a novel inhaled dual antimuscarinic/β2 agonist (abstract). Eur Respir J 2010;36:1231.
33. Anzueto A, Leimer I, Kesten S. Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes. Int J Chron Obstruct Pulmon Dis 2009;4:245-51. http://dx.doi.org/10.2147/COPD.S4862
34. Camargo CA Jr, Tsai CL, Clark S, Kenney PA, Radeos MS. Spirometric correlates of dyspnea improvement among emergency department patients with chronic obstructive pulmonary disease exacerbation. Respir Care 2008;53(7):892-6.
35. Niewoehner DE. Relation of chronic obstructive pulmonary disease exacerbations to FEV(1)--an intricate tango. Respiration 2009;77(2):229-35. http://dx.doi.org/10.1159/000162877
36. Watson L, Schouten JP, Lofdahl CG, et al. Predictors of COPD symptoms: does the sex of the patient matter? Eur Respir J 2006;28(2):311-18. http://dx.doi.org/10.1183/?09031936.06.00055805
37. Mannino DM, Davis KJ. Lung function decline and outcomes in an elderly population. Thorax 2006;61(6):472-7. http://dx.doi.org/10.1136/thx.2005.052449
38. McGlone S, Venn A, Walters EH, Wood-Baker R. Physical activity, spirometry and quality-of-life in chronic obstructive pulmonary disease. COPD 2006;3(2):83-8. http://dx.doi.org/10.1080/15412550600651263
39. Jones PW, Donohue J, Nedelman J, Pinault G, Pascoe S. Correlating changes in lung function with patient reported outcomes in COPD (abstract). Thorax 2010; 65:A141. http://dx.doi.org/10.1136/thx.2010.150987.49